# Artiva Biotherapeutics, Inc.: overview ARTV · Nasdaq · CIK 1817241 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/artv.md) · [Financials](/companies/artv/financials.md) · [Filings](/companies/artv/filings.md) · [Insiders](/companies/artv/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-100135.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K filed Mar 10, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-100135). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0 d](/filings/0001193125-25-275872.md) | [0.0 d](/filings/0001193125-26-100135.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.92)](/filings/0001193125-25-275872.md) | not reported | [(0.83)](/filings/0001193125-26-213242.md) | [(0.87)](/filings/0001193125-26-338029.md) | [(0.88)](/filings/0001193125-25-275872.md) | not reported | [(0.95)](/filings/0001193125-26-213242.md) | [(0.63)](/filings/0001193125-26-338029.md) | | Free cash flow | $m | [(11.7) d](/filings/0001193125-25-275872.md) | [(14.7) d](/filings/0001193125-26-100135.md) | [(20.4)](/filings/0001193125-26-213242.md) | [(24.0) d](/filings/0001193125-26-338029.md) | [(19.8) d](/filings/0001193125-25-275872.md) | [(15.1) d](/filings/0001193125-26-100135.md) | [(21.2)](/filings/0001193125-26-213242.md) | [(20.8) d](/filings/0001193125-26-338029.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | [32.9](/filings/0000950170-25-043837.md) | [0.3](/filings/0001193125-26-100135.md) | [0.0](/filings/0001193125-26-100135.md) | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | [(93.2%)](/filings/0000950170-25-043837.md) | [(26805.6%)](/filings/0001193125-26-100135.md) | not reported | | Net margin | % | [(87.2%)](/filings/0000950170-25-043837.md) | [(26045.0%)](/filings/0001193125-26-100135.md) | not reported | | Diluted EPS | $ per share | [(35.78)](/filings/0000950170-25-043837.md) | [(5.81)](/filings/0001193125-26-100135.md) | [(3.43)](/filings/0001193125-26-100135.md) | | Free cash flow | $m | [(50.7)](/filings/0000950170-25-043837.md) | [(55.7)](/filings/0001193125-26-100135.md) | [(79.3)](/filings/0001193125-26-100135.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/artv/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $174.2m | 17,955,642 | | Added +8,102,340 | | [VIKING GLOBAL INVESTORS LP](/funds/1103804.md) | 2026-06-30 | $25.3m | 2,604,166 | | New +2,604,166 | | [Blackstone Inc.](/funds/1393818.md) | 2026-06-30 | $23.3m | 2,403,437 | | New +2,403,437 | | [5AM Venture Management, LLC](/funds/1799883.md) | 2026-06-30 | $22.8m | 2,353,304 | | Unchanged | | [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $19.8m | 2,043,596 | | Added +434,027 | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $19.4m | 1,997,223 | | Added +1,476,896 | | [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $16.8m | 1,736,111 | | New +1,736,111 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $9.5m | 981,815 | | Added +774,129 | | [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $9.3m | 954,861 | | New +954,861 | | [Blue Owl Capital Holdings LP](/funds/1858703.md) | 2026-06-30 | $8.5m | 874,542 | | New +874,542 | ## Recent filings [All 226 filings](/companies/artv/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 08:30 ET | [8-K](/filings/0001193125-26-432806.md) | 2.02 Results of operations; 2.05 Exit or disposal costs; 9.01 Financial statements and exhibits | 0001193125-26-432806 | | 2026-09-11 | 16:21 ET | [8-K](/filings/0001193125-26-389308.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-389308 | | 2026-08-06 | 16:12 ET | [10-Q](/filings/0001193125-26-338029.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338029 | | 2026-08-06 | 16:09 ET | [8-K](/filings/0001193125-26-337986.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-337986 | | 2026-08-03 | 16:08 ET | [DEF 14A](/filings/0001193125-26-330563.md) | Proxy statement, period 2026-09-08 | 0001193125-26-330563 | | 2026-07-23 | 21:23 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000203.md) | Ownership report, active investor, amended | 0001346824-26-000203 | | 2026-07-22 | 17:15 ET | [8-K](/filings/0001193125-26-312560.md) | 8.01 Other events | 0001193125-26-312560 | | 2026-06-15 | 19:37 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000173.md) | Ownership report, active investor, amended | 0001346824-26-000173 | | 2026-05-28 | 16:38 ET | [SCHEDULE 13D/A](/filings/0001931382-26-000009.md) | Ownership report, active investor, amended | 0001931382-26-000009 | | 2026-05-19 | 08:07 ET | [8-K](/filings/0001193125-26-229714.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-229714 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-100135.md), filed Mar 10, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1817241 - Tickers: ARTV - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 08:31 ET. No prices; not investment advice.